Anthropometric Measurements as Predictors of Low Birth Weight Among Tanzanian Neonates: A Hospital-Based Study
November 7, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Nulojix
Synonyms :
belatacept
Class :
Selective T-Cell Co-stimulation Blockers, Immunosuppressants
Brand Name :
Nulojix
Synonyms :
belatacept
Class :
Selective T-Cell Co-stimulation Blockers, Immunosuppressants
Dosage Forms & StrengthsÂ
Powder for reconstitution lyophilised injectionÂ
250mg/vialÂ
Prophylaxis Of Kidney Transplant RejectionÂ
Indicated for usage in conjunction with mycophenolate mofetil, basiliximab induction, and corticosteroids to avoid rejection after a kidney transplant
:
Dosage schedule and calculation
Total infusion dosage depends on the patient's weight at the transplant time; the dose should be changed if weight varies by more than 10%.
To precisely create the prescribed dosage from the reconstituted solution, the dosage must be divisible by 12.5 mg.
Initial dose: Administer 10 mg/kg intravenously on transplant day (before implantation); repeat the same on day five and at the end of the 2nd,4th,8th, and 12th weeks after the transplantation.
Maintenance dose: After the transplantation, administer 5 mg/kg intravenously at the end of Week 16 and every four weeks (within +/- three days).
<18 years: Safety and efficacy not establishedÂ
Refer adult dosingÂ
may decrease the diagnostic effect of Immunosuppressants
may decrease the therapeutic effect of Immunosuppressants
may increase the immunosuppressive effect of Immunosuppressants
may decrease the therapeutic effect of Immunosuppressants
may increase the immunosuppressive effect of Immunosuppressants
may decrease the therapeutic effect of Immunosuppressants
respiratory syncytial virus vaccine, adjuvanted
may decrease the therapeutic effect of Immunosuppressants
respiratory syncytial virus (RSV) vaccine
may decrease the therapeutic effect of Immunosuppressants
may decrease the therapeutic effect of Immunosuppressants
may enhance the risk of adverse effects when combined with belatacept
antithymocyte globulin equineÂ
may increase the adverse effect of Antithymocyte Globulin
antithymocyte globulin rabbitÂ
antithymocyte globulin (Rabbit): it may increase the toxic effect of belatacept
may increase the adverse effect of Immunosuppressants
may increase the immunosuppressive effect of Immunosuppressants
may increase the immunosuppressive effect of Immunosuppressants
may increase the immunosuppressive effect of Immunosuppressants
relugolix/​estradiol/​norethindrone
may increase the hypertensive effect of Hypertension-Associated Agents
relugolix/estradiol/norethindrone
may increase the hypertensive effect of Hypertension-Associated Agents
may increase the hypertensive effect of Hypertension-Associated Agents
may increase the hypertensive effect of Hypertension-Associated Agents
may increase the hypertensive effect of Hypertension-Associated Agents
may decrease the therapeutic effect of Fc Receptor-Binding Agents
it may enhance the risk of side effects when combined with mitomycin
When mometasone furoate is used together with belatacept, this leads to enhanced risk or seriousness of adverse outcomes
belatacept lessens the effects of the H5N1 influenza vaccine
antithymocyte globulin rabbitÂ
the risk or extent of adverse effects can be raised when anti-thymocyte immunoglobulin (rabbit) is combined with belatacept
By immunosuppressive effects, the both the drugs action either decreases and results in risk of infection.
when belatacept and melphalan combine the immunosuppressive effects of both the drugs are enhanced and lead to increased risk of infection
when both the drugs combine the effect of both drugs increases by immunosuppressive effects and increase the risk of infection.
interaction increases the risk of excessive immunosuppression
may enhance immunosuppressive effects of daunorubicin
both the drugs increase the effect of immunosuppression risk of infection increases on administering both the drugs simultaneously
may increase excessive immunosuppressive effects and raise the risk of infection
increase immunosuppressive effects and risk of infection
when used in combination, both the drugs increase immunosuppression/risk of infection
increase immunosuppressive effects and risk of infection
increase immunosuppressive effects and risk of infection
either of the drug in combination increases the effect of the other due to immunosuppression/risk of infection
May increase excessive immunosuppressant activity docet
may enhance immunosuppressive effects of idarubicin
may enhance the immunosuppressive effects of each other
the risk of adverse effects can be increased
the risk of adverse effects may be increased
the risk of adverse effects may be increased
Actions and Spectrum:Â
Frequency definedÂ
>10%Â
Diarrhea (39%)Â
Peripheral edema (34%)Â
Hypertension (32%)Â
Graft dysfunction (25%)Â
Nausea (24%)Â
Headache (21%)Â
Anemia (45%)Â
Urinary tract infection (37%)Â
Constipation (33%)Â
Pyrexia (28%)Â
Cough (24%)Â
Vomiting (22%)Â
Hyperkalemia (20%)Â
Dyslipidemia (19%)Â
Hypophosphatemia (19%)Â
Arthralgia (17%)Â
Hematuria (16%)Â
Hypokalemia (21%)Â
Leukopenia (20%)Â
Abdominal pain (19%)Â
Hypotension (18%)Â
Hyperglycemia (16%)Â
Proteinuria (16%)Â Â
1-10%Â Â
Bronchitis (10%)Â
New onset diabetes (8%)Â
Hypomagnesemia (7%)Â
Anxiety (10%)Â
Renal tubular necrosis (9%)Â
Acne (8%)Â
Hyperuricemia (5%)Â Â
Post-marketing reportsÂ
AnaphylaxisÂ
Black box warning:Â
Contraindications/caution:Â
Contraindications:Â
Caution:Â
Pregnancy consideration: Insufficient data availableÂ
Lactation: Excretion of the drug in human breast milk is unknownÂ
Pregnancy category:Â
Category A: well-controlled and Satisfactory studies show no risk to the fetus in the first or later trimester.Â
Category B: there was no evidence of risk to the fetus in animal studies, and there were not enough studies on pregnant women.Â
Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.   Â
Category D: adequate data with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.   Â
Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.   Â
Category N: There is no data available for the drug under this categoryÂ
Pharmacology:Â
belatacept acts as a fusion protein that binds to CD80 and CD86 on APCs, preventing their interaction with CD28 on T cells. By blocking this co-stimulatory signal, belatacept inhibits T cells’ activation, proliferation, and differentiation, ultimately suppressing the immune response.Â
Pharmacodynamics:Â
Pharmacokinetics:Â
AbsorptionÂ
belatacept is administered intravenously (IV) and directly introduced into the bloodstream. Â
DistributionÂ
belatacept distributes into the extravascular space, including peripheral tissues. It is believed to bind to CD80/86 on antigen-presenting cells (APCs) in various tissues.Â
MetabolismÂ
belatacept is a fusion protein composed of the extracellular domain of human cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) and a modified Fc region of human immunoglobulin G1 (IgG1). Â
Elimination and ExcretionÂ
belatacept is primarily eliminated from the body through catabolism and renal excretion.
Administration:Â
Patient information leafletÂ
Generic Name: belataceptÂ
Why do we use belatacept?Â
belatacept is primarily used as an immunosuppressive medication in adult kidney transplant recipients. It is indicated for the prevention of organ rejection following kidney transplantation.Â
The specific uses of belatacept include:Â
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
